Aerie Pharmaceuticals, Inc.

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

After its spin-out from Novartis AG in 2019, ophthalmology specialist Alcon Inc. has steadily expanded its pharmaceutical portfolio and formed a dedicated sales channel to focus specifically on ey

Ophthalmology specialist Alcon Inc. will buy Aerie Pharmaceuticals, Inc. for roughly $770m, gaining two commercial products for glaucoma, a Phase III drug candidate for dry eye disease and other e

When asked to sum up what Santen Pharmaceutical Co., Ltd. sees as its broad health mission, the Japanese ophthalmology company’s president and CEO does not hesitate. “There is a global focus on eye